sPLA2 inhibitor 1 is primarily used in research and therapeutic contexts targeting secretory phospholipase A2 (sPLA2) enzymes, which are involved in inflammatory processes. It is utilized to study the role of sPLA2 in various diseases, such as atherosclerosis, arthritis, and sepsis, by blocking its activity. This inhibition helps reduce the production of pro-inflammatory mediators like prostaglandins and leukotrienes, making it a potential candidate for anti-inflammatory drug development. Additionally, it is explored for its neuroprotective effects in conditions like Alzheimer's disease, where sPLA2 activity contributes to neuronal damage. Its application extends to cancer research, as sPLA2 is implicated in tumor progression and metastasis. Overall, it serves as a valuable tool for understanding and modulating sPLA2-related pathways in disease mechanisms.